Obesity-related genes and their proteins and uses thereof
AssigneeThe Trustees of Columbia University in the City of New York
InventorsJosé Leonardo WALEWSKI, Paul David BERK
Life of this patent
Estimating the term…
Abstract
The invention provides for methods of treating obesity or an obesity-associated disorder.
Claims50
A method for treating obesity or an obesity-associated disorder in a subject, the method comprising administering to a subject an effective amount of Spexin, thereby treating obesity or an obesity-associated disorder in the subject.
A method for treating obesity or an obesity-associated disorder in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising SEQ ID NO:
- 1, or a pharmaceutically acceptable salt thereof, thereby treating obesity or an obesity-associated disorder in the subject.
A method for promoting satiety in an obese subject or a subject afflicted with an obesity-associated disorder, the method comprising administering to a subject an effective amount of Spexin, thereby promoting satiety in an obese subject.
A method for promoting satiety in an obese subject or a subject afflicted with an obesity-associated disorder, the method comprising administering to a subject in need thereof a polypeptide comprising SEQ ID NO:
- 1, or a pharmaceutically acceptable salt thereof, thereby promoting satiety in an obese subject.
A method of promoting weight loss in an obese subject or a subject afflicted with an obesity-associated disorder, the method comprising:
- a) administering to a subject an effective amount of Spexin;
- and
- b) determining whether Spexin decreased the subject's body mass as compared to the subject's body mass prior to treatment with Spexin,
- thereby promoting weight loss in the obese subject or the subject afflicted with an obesity-associated disorder.
A method of promoting weight loss in an obese subject or a subject afflicted with an obesity-associated disorder, the method comprising:
- a) administering to a subject in need thereof a therapeutic amount of a polypeptide comprising SEQ ID NO:
- 1 or a pharmaceutically acceptable salt thereof;
- and
- b) determining whether the polypeptide comprising SEQ ID NO:
- 1 decreased the subject's body mass as compared to the subject's body mass prior to treatment with polypeptide comprising SEQ ID NO:
- 1,
- thereby promoting weight loss in the obese subject or the subject afflicted with an obesity-associated disorder.
A method of decreasing serum Leptin levels in an obese subject or a subject afflicted with an obesity-associated disorder, the method comprising:
- a) administering to a subject an effective amount of Spexin;
- and
- b) determining whether Spexin decreased the subject's serum Leptin levels as compared to the subject's serum Leptin levels prior to treatment with Spexin,
- thereby decreasing serum Leptin levels in the obese subject or the subject afflicted with an obesity-associated disorder.
A method of decreasing serum Leptin levels in an obese subject or a subject afflicted with an obesity-associated disorder, the method comprising:
- a) administering to a subject in need thereof a therapeutic amount of a polypeptide comprising SEQ ID NO:
- 1 or a pharmaceutically acceptable salt thereof and
- b) determining whether the polypeptide comprising SEQ ID NO:
- 1 decreased the subject's serum Leptin levels as compared to the subject's serum Leptin levels prior to treatment with polypeptide comprising SEQ ID NO:
- 1,
- thereby decreasing serum Leptin levels in the obese subject or the subject afflicted with an obesity-associated disorder.
A method for detecting the presence of or a predisposition to obesity or an obesity-associated disorder in a human subject, the method comprising:
- (a) obtaining a biological sample from a subject;
- and
- (b) detecting whether or not there is an alteration in the expression of a Obesity-Signature (OS) gene in the subject as compared to a subject not afflicted with obesity or an obesity-associated disorder.
A diagnostic kit for determining whether a sample from a subject exhibits increased or decreased expression of at least 2 or more OS genes, the kit comprising nucleic acid primers that specifically hybridize to a OS gene, wherein the primer will prime a polymerase reaction only when a OS gene in any one of Tables 7-8, Spexin, or a combination thereof, is present.
A method for identifying a Spexin-modulating compound useful for treating obesity or an obesity-associated disorder in a subject, the method comprising:
- (a) administering a test agent to a mouse model of obesity or an obesity-associated disorder;
- and
- (b) determining whether the test agent altered serum Spexin levels, serum Leptin levels, a body-weight phenotype, or a combination thereof, as compared to a mouse in the absence of the test agent,
- thereby identifying a compound useful for treating obesity or an obesity-associated disorder.
Dependencies are inferred from the claim text.